IRB #

STUDY00018084

Title

[NCI CIRB] S1609, "DART: DUAL ANTI-CTLA-4 AND ANTI-PD-1 BLOCKADE IN RARE TUMORS”

Principal Investigator

Christopher Ryan

Study Purpose

The purpose of this study is to test the effectiveness (how well the drug works), safety, and tolerability of combinatorial immune checkpoint blockade with ipilimumab plus nivolumab in participants with rare cancer types.

Medical Condition(s)

This trial will accrue to 31 histology-defined strata as well as a stratum for cancers of unknown primary and a stratum for other rare tumors not specified in the prior strata.

Eligibility Criteria

1. Must be 18 years of age or older
2. Subject must have confirmed diagnosis of rare cancer identified in protocol
3. Patients must have had at least one line of standard treatment for their rare cancer
4. Have tumor samples available for testing
5. Subject's medical history will be reviewed in detail for study eligibility

Age Range

18 - 120

Healthy Volunteers Needed

No

Duration of Participation

Patients will stay in the study as long as they receive clinical benefit.

Minors Included

No

Contact

Knight Clinical Trials Hotline
503 494-1080
trials@ohsu.edu

Sponsor

SWOG (Southwest Oncology Group)

Recruitment End

12/31/2020

Compensation Provided

No


Go Back